Preoperative Thrombocytosis is Not Associated with Overall Survival in 309 Glioblastoma Patients

Abstract

Background In recent years, a correlation of thrombocytosis and a worse prognosis was shown for many solid cancers, including glioblastoma multiforme (GBM).

Methods A retrospective review was performed for all patients with a histologically proven and first-diagnosed GBM between 2005 and 2015 in our department. Clinical and paraclinical parameters were acquired from patient documentation and structured for subsequent data analysis. The association of potential risk factors with overall survival was assessed using the Kaplan–Meier survival analysis and Cox regression.

Results The present study includes 309 patients first diagnosed with primary GBM. Our analyses validate well-known risk factors of a decreased overall survival such as higher patient age, a larger preoperative tumor volume, Karnofsky performance status, extent of resection, tumor localization, and adjuvant treatment. However, no correlation was observed between a preoperative thrombocytosis, the mean platelet volume, leucocyte count, activated partial thromboplastin time (apTT), fibrinogen level, and acetylsalicylic acid 100 co-medication. Patients with preoperative hemoglobin below 7.5 mmol/L had decreased overall survival.

Conclusion The present study, enrolling the largest numbers of patients assessing this topic to date, did not find any association between a preoperative thrombocytosis and overall survival in 309 patients with GBM.

Keywords

platelet count - overall survival - glioblastoma - aspirin - hemoglobin

Publikationsverlauf

Eingereicht: 01. Dezember 2020

Angenommen: 14. Mai 2021

Artikel online veröffentlicht:
12. Dezember 2021

• References

• 1 Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007; 5 (Suppl. 01) 246-254
• 2 Buergy D, Wenz F, Groden C, Brockmann MA. Tumor-platelet interaction in solid tumors. Int J Cancer 2012; 130 (12) 2747-2760
• 3 Stupp R, Mason WP, van den Bent MJ. et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10) 987-996
• 4 Brockmann MA, Giese A, Mueller K. et al. Preoperative thrombocytosis predicts poor survival in patients with glioblastoma. Neuro-oncol 2007; 9 (03) 335-342
• 5 Lopes M, Carvalho B, Vaz R, Linhares P. Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme. J Neurooncol 2018; 136 (01) 173-180
• 6 Cho SY, Yang JJ, You E. et al. Mean platelet volume/platelet count ratio in hepatocellular carcinoma. Platelets 2013; 24 (05) 375-377
• 7 Inagaki N, Kibata K, Tamaki T, Shimizu T, Nomura S. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer 2014; 83 (01) 97-101
• 8 Osada J, Rusak M, Kamocki Z, Dabrowska MI, Kedra B. Platelet activation in patients with advanced gastric cancer. Neoplasma 2010; 57 (02) 145-150
• 9 Wang X, Cui MM, Xu Y. et al. Decreased mean platelet volume predicts poor prognosis in invasive bladder cancer. Oncotarget 2017; 8 (40) 68115-68122
• 10 Cappellini MD, Motta I. Anemia in clinical practice-definition and classification: does hemoglobin change with aging?. Semin Hematol 2015; 52 (04) 261-269
• 11 Lombardi G, Rumiato E, Bertorelle R. et al. Clinical and genetic factors associated with severe hematological toxicity in glioblastoma patients during radiation plus temozolomide treatment: a prospective study. Am J Clin Oncol 2015; 38 (05) 514-519
• 12 Zhang F, Guo X, Xing B, Yang Y, Xu Z. Hepatic and renal functions and blood cell counts in brain tumor patients during the perioperative period. J Clin Neurosci 2019; 69: 190-197
• 13 Wick W, Weller M, van den Bent M. et al. MGMT testing: the challenges for biomarker-based glioma treatment. Nat Rev Neurol 2014; 10 (07) 372-385
• 14 Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The platelet-cancer loop. Eur J Intern Med 2013; 24 (05) 393-400
• 15 Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol 2010; 30 (12) 2362-2367
• 16 Williams M, Liu ZW, Woolf D. et al. Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival. J Cancer Res Clin Oncol 2012; 138 (10) 1683-1688
• 17 Marx S, Splittstöhser M, Kinnen F. et al. Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients. Oncotarget 2018; 9 (40) 25860-25876
• 18 Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res 2013; 19 (12) 3165-3175
• 19 Markovic DS, Vinnakota K, Chirasani S. et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc Natl Acad Sci U S A 2009; 106 (30) 12530-12535
• 20 Ye XZ, Xu SL, Xin YH. et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J Immunol 2012; 189 (01) 444-453
• 21 Jimsheleishvili S, Alshareef AT, Papadimitriou K. et al. Extracranial glioblastoma in transplant recipients. J Cancer Res Clin Oncol 2014; 140 (05) 801-807
• 22 Müller C, Holtschmidt J, Auer M. et al. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med 2014; 6 (247) 247ra101
• 23 Nilsson RJ, Balaj L, Hulleman E. et al. Blood platelets contain tumor-derived RNA biomarkers. Blood 2011; 118 (13) 3680-3683
• 24 Meikle CK, Kelly CA, Garg P, Wuescher LM, Ali RA, Worth RG. Cancer and thrombosis: the platelet perspective. Front Cell Dev Biol 2017; 4: 147
• 25 Placke T, Kopp HG, Salih HR. Modulation of natural killer cell anti-tumor reactivity by platelets. J Innate Immun 2011; 3 (04) 374-382
• 26 Han S, Liu Y, Li Q, Li Z, Hou H, Wu A. Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC Cancer 2015; 15: 617
• 27 Subeikshanan V, Dutt A, Basu D, Tejus MN, Maurya VP, Madhugiri VS. A prospective comparative clinical study of peripheral blood counts and indices in patients with primary brain tumors. J Postgrad Med 2016; 62 (02) 86-90
• 28 Daugherty SE, Pfeiffer RM, Sigurdson AJ. et al. Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol 2011; 173 (07) 721-730
• 29 Brockmann MA, Bender B, Plaxina E. et al. Differential effects of tumor-platelet interaction in vitro and in vivo in glioblastoma. J Neurooncol 2011; 105 (01) 45-56